DNK-ADUFLU-3

A Phase II Study to Assess the Safety and Immunogenicity of subcutaneous DNK-FLU in Healthy Japanese Adults

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222415

Enrollment

Registered

2014-03-05

Start date

2014-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of influenza infection

Interventions

investigational material(s) Generic name etc : DNK-FLU INN of investigational material : Therapeutic category code : 631 Vaccines Dosage and Administration for Investigational material : subcutaneous

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Adults

Exclusion criteria

Exclusion criteria: Known history of influenza or received influenza vaccination within six months.

Design outcomes

Primary

Measure	Time frame
Safety Adverse Event	—

Secondary

Measure	Time frame
Immunogenicity HI antibody titer against antigen Neutralizing antibody titer against influenza virus	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026